ArticleHealth science reports2026
Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) in a Hospital Triage Population in Tehran During 2024-2025.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) in a Hospital Triage Population in Tehran During 2024-2025.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that is associated to adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) as two major diseases of the virus. Due to limited data on its prevalence in general populations in Tehran and as this virus is endemic in Iran, this study aimed to assess HTLV-1 prevalence among patients attending the triage unit of Imam Khomeini Hospital during 2024-2025. Methods: In this cross-sectional study conducted between 2024 and 2025, patients presenting to the triage unit were randomly selected. Exclusion criteria included active infection with HBV, HCV, or HIV, and receiving antiretroviral therapy (ART). After obtaining informed consent, 5 mL of whole blood was collected from each participant. The DNJIA kit (ROJE Technologies, Iran) was used to extract DNA. We used primers that targeted the HBZ and Tax regions of the viral genome to do PCR amplification to find HTLV-1. Results: Out of 197 individuals enrolled in this cross-sectional study, 1 participant (0.51%) was positive for HTLV-1. The HTLV-1-positive case was a 40-year-old single male with a history of both blood transfusion and prior surgery, but no history of organ transplantation, substance addiction, or travel. Most of the people who took part were men (54.3%) and married (58.9%), and their average age was 39.7 ± 12.1 years. Fisher's exact test showed a statistically significant association between HTLV-1 positivity and a history of blood transfusion ( Conclusion: The only positive case (0.51%) had known risk factors associated to HTLV-1 infection including prior surgery and blood transfusion. Given the higher reported prevalence of HTLV-1 in endemic regions including Iran, and the increased risk among certain populations-such as individuals with a history of intravenous drug use, multiple sexual partners, or co-infection with other viruses-future studies should focus on these high-risk groups and the virus prevalence over time. Targeted screening in such populations may provide a more accurate picture of the virus's distribution during different time frames for more effective control and prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.